Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : National Institute on Aging | H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : National Institute on Aging | H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lundbeck Partners with Takeda in the US, Opts for Royalties, Focuses on Rexulti
Details : Lundbeck will cease all promotional efforts for Trintellix (vortioxetine hbr) with Takeda in the U.S. fully reallocate resources to other growth opportunities and accelerate growth for these products.
Product Name : Trintellix
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 08, 2024
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : USFDA has given tentatively approved ANDA, a therapeutically equivalent reference listed drug product for Vortioxetine-Generic (Vortioxetine), indicated for the treatment of major depressive disorder.
Product Name : Vortioxetine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 01, 2022
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : H. Lundbeck AS
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries1 , including the US, EU, Canada and Australia.
Product Name : Vortidif
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 30, 2022
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : H. Lundbeck AS
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Rawalpindi Medical College
Deal Size : Inapplicable
Deal Type : Inapplicable
Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Rawalpindi Medical College
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vortioxetine to Prevent Return of Symptoms in Children With Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2021
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In a new real-world study, the ability of Trintellix/Brintellix® (vortioxetine) to improve functioning in family, social, and work life for people living with Major Depressive Disorder was assessed.
Product Name : Trintellix
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2021
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Study Finds that Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder
Details : A new study shows that people living with Major Depressive Disorder (MDD) and comorbid Generalized Anxiety Disorder (GAD) benefit from treatment with vortioxetine as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).
Product Name : Trintellix
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2020
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Vortioxetine in Patients With Depression and Early Dementia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2020
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable